7/27/2019 Penanganan Gagal Nafas Warna
1/55
Diagnosis and Management of Acute Respiratory Failure (ARF)
Dr. Prabowo Wicaksono Y.P., SpAn
Department of Anesthesiology
UNISSULA Medical Faculty/ RSI Sultan Agung
Semarang
2007
7/27/2019 Penanganan Gagal Nafas Warna
2/55
I. DEFINITION/ CLASSIFICATION OF ARF
ARF : One of the most common disorders leading to ICU admission
Occurs when pulmonary systems is no longer able to meet the metabolicdemand of the body.
Pulmonary system : 2 metabolic roles:
- Oxygenation of arterial blood
- Elimination of CO 2
Two basic types of RF:
TYPE I : Hypoxemic . Interference with the pulmonary systemss ability toadequately oxygenate the blood as is circulates through the alveolar
capillaries. PaO 2 (room air) < 60 mmHg. (Normal PaO 2: 75-100 mmHg). TYPE II : Hypercapnic . Failure to prevent CO2 retention (e.g., severeairflow obstruction, central resp. failure, neuromuscular resp. failure)PaCO 2 > 50 mmHg. (Normal PaCO 2: 35-45 mmHg)
7/27/2019 Penanganan Gagal Nafas Warna
3/55
II. CAUSES OF ARF
RF may results from primary pulmonary insults and from other systemicnonpulmonary disorders (CNS, CV, neuromuscular systems, upper and lower
airways, pulmonary parenchyma). Often multifactorial.CAUSES OF RESPIRATORY FAILURE
Disorders associated with Abnormal Oxygen Onloading (Hypoxemic RF)
Lower Airway and Parenchyma
NEOPLASM TRAUMA (pulmo. contusion, laseration ARDS
INFECTION OTHER (Broncospasm, CHF) Interstitial lung disease
Pulmonary emboli
Atelectasis
Cystic fibrosis
Disorders associated with Inadequate CO2 Offloading (Hypercapneic RF)
BRAIN : Drugs (opioids, benzodiazepines, propofol, barbiturates, GA, poisons)
Metabolic (e.g.Hyperglycemia, hypocalcemia)
Neoplasma, Infection, Increased ICP.
NERVES AND MUSCLES: trauma, metabolic, drugs, poisons, neoplasm, infection
7/27/2019 Penanganan Gagal Nafas Warna
4/55
UPPER AIRWAY: Tissue enlargement, infenction, trauma.
CHEST BELLOWS: trauma (rib fractures, flail chest), other contributing factors (e.g.obesity,ascites, spondylitis)
III. PATHOPHYSIOLOGY OF ACUTE RESPIRATORY FAILUREA. HYPOXEMIA
The underlying physiologic abberation in hypoxemic RF is usually the resultsof a mismatch of alveolar ventilation and pulmonary perfusion . Diseasesprocesses that cause progressive obstruction or atelectasis (e.g. pneumonia,aspiration, edema) results in decrease in the amount of oxygen available indistal airways for uptake .
This mismatch of ventilation (V) and perfusion (Q) wherein perfusion isrelatively greater than ventilation to a given lung unit is called shunt effect .The venous blood entering pulmonary capillaries acts as if did not travel to
the lung at all because it remains relatively poorly oxygenated as it returns tothe left atrium , the physiologic effect of this type of V/Q mismatch ishypoxemia.
Treatment should be directed toward removing obstruction, reopeningatelectasis zones, and preventing closure of the affected lung units.
The most likely reason for a patient to be hypoxemic is this type of V/Qmismatch.
7/27/2019 Penanganan Gagal Nafas Warna
5/55
7/27/2019 Penanganan Gagal Nafas Warna
6/55
ALVEOLUS
PULMONARYCAPILLARY
FREE AIR:
PiO2 : 20.9 % x 760 = 159 mmHg
PiCO2 : 0.04 % x 760 = 0.3 mmHg
PiN2 : 78.6 % x 760 = 597mmHg
PiH2O : 0.46 % x 760 = 3.5 mmHg N2 H2O
O2
PAO2:104 mmHg
CO2
PACO2:40 mmHg
O2PaO2:40 mmHg
O2
PaO2:104 mmHg
CO2PaCO2:45 mmHg
CO2PaCO2:40 mmHg
DIFUSSIONPROCESS
PAN2:573 mmHg
PAH2O:47 mmHg
7/27/2019 Penanganan Gagal Nafas Warna
7/55
B. HYPERCAPNIA
Hypercapnia RF is caused by one or more factors describes in equation foalveolar minute ventilation:
VA= (VT-VD) . f VA : minute alveolar ventilation
VT : tidal volume
VD : physiologic dead space (alveolus is well ventilted but poorly perfused)
f : respiration frequencyHypercapnia may results from decreased VT or f as occurs with drug ingestion,anestesia, change in medullary center for respiration, fatigue. An elevatedPaCO 2 normally increases ventilatory drive. Therefore, hypercapnic respiratoryfailure may also imply that the patient is:
- Unable to sense the elevated PaCO 2 due to drug, alkalemia, COPD, etc- Unable to neurologically signal the effector mechanism of ventilation becauseof spinal cord injury, neuromuscular blockade, Guillan- Barre synd, MyasteniaGravis.
- Unable to effect a response from the muscle of respiration because of fatigue,malnutrition etc.
7/27/2019 Penanganan Gagal Nafas Warna
8/55
Tratment of decrease VT or respiration rate may require special medications(e.g. for Myastenia), reversal of sedation or other drugs, intubation/ mechanicalventilation to rest fatigued muscles, nutrition, resp. stimulant and as alwaystreatment of other possible primary cause.
Increased physiologic dead space (VD) may also produce hypercapnia andrepresents the other type of V/Q mismatch. When gas flow to and from airwaysremain adequate but blood flow is absolutely or relatively diminished, CO 2 doesnot have the opportunity to diffuse from the pulmonary artery blood, and CO 2 rich blood is returned to the left atrium. This condition may occur in
hypovolemia, pulmonary embolus, poor cardiac output.IV. MANIFESTATIONS OF ARF
Clinical manifestations of respiratory distress commonly reflect signs andsymptoms of hypoxemia, hypercapnia, or both. These include:
-Altered mental status, ranging from agitation to somnolence.-Evidence of increased work of breathing (i.e., nasal flaring, use of accessorymuscles, intercostal/suprasternal/supraclavicular retraction, tachypnea,hyperpnea, or a paradoxical breathing pattern)
- Bradypnea
7/27/2019 Penanganan Gagal Nafas Warna
9/55
- Cyanosis of mucosal membranes (e.g., tongue, mouth) or nail beds.
- Diaphoresis, tachycardia, hypertension, and other sign of catecolamine release.
Laboratory test :- A key test is the arterial blood gas (PaO 2 and PaCO 2, to differentiate between
ARF type I and II )
- Additional test: electrolytes, drug level : clue to underlying etiology of ARF
- A chest radiograph: pumonary infiltrates: a hypoxemic component for ARF, aclear lung fields suggest possible hypercapnic RF, although considerable overlapexists.
7/27/2019 Penanganan Gagal Nafas Warna
10/55
MANAGEMENT
1. Clear the airway
2. Oxygen supplementation
3. Noninvasive positive pressure ventilation
4. Tracheal intubation and mechanical ventilation
5. Pharmacologic adjuncts
7/27/2019 Penanganan Gagal Nafas Warna
11/55
PRIMARY SURVEYAirway : Open the airwayBreathing : Provide positive-pressure
ventilationCirculation : Give chest compressionsDefibrillation : Shock VF / pulseless VT
Airway : Establish advanced airway
control Perform endotracheal
intubationBreathing : Assess the adequacy of
ventilation via endotrachealtube
Provide positive-pressure
ventilationsCirculation : Obtain iv access Continue CPR Provide rhythm cv
Differential Diagnosis
SECONDARY SURVEY1. CLEAR THE AIRWAY
7/27/2019 Penanganan Gagal Nafas Warna
12/55
Airway obstruction causedinadequate ventilation although thepatient breathing sontaneously. Thecaused of obstruction:
Tongue, epiglottisForeign object
LIDAHOBSTRUKSI AIRWAY
AIRWAY OBSTRUCTION
7/27/2019 Penanganan Gagal Nafas Warna
13/55
PRIMARY PRIORITY: CLEAR THE AIRWAY
Manual: Triple airway maneuver: - Head Tilt
- Chin lift
- Jaw Thrust Airways : - Oropharyngeal airways (Guedel)
- Nasopharyngeal airways- Laryngeal mask airway
Endotracheal Intubation
7/27/2019 Penanganan Gagal Nafas Warna
14/55
HEAD TILT CHIN LIFTCAUTIONS !!! CERVICALTRAUMA ??
7/27/2019 Penanganan Gagal Nafas Warna
15/55
JAW THRUST
7/27/2019 Penanganan Gagal Nafas Warna
16/55
Oropharyngeal Airway
To prevent obstruction of hypofaring by the tongue
To facilitate suctionTo prevent tongue or ETT
bite
Unconscious patientwithout gag reflect.
7/27/2019 Penanganan Gagal Nafas Warna
17/55
Oropharyngeal Airway/Guedel
7/27/2019 Penanganan Gagal Nafas Warna
18/55
Measure the right size of Oropharyngeal airway/Guedel
Complication :Total obstructionLaringospasmVomit
7/27/2019 Penanganan Gagal Nafas Warna
19/55
Oropharyngeal airway
How to insert correctly
7/27/2019 Penanganan Gagal Nafas Warna
20/55
Nasopharyngeal Airway
Indication:- Spontaneous breathing, unconscious patient.- Better tolerated than OPA
7/27/2019 Penanganan Gagal Nafas Warna
21/55
Nasopharyngeal Airway
Complication Nasal mocous damaged
Laryngospasme
7/27/2019 Penanganan Gagal Nafas Warna
22/55
How to insert Nasophryngeal Airway1.
2. 3.
7/27/2019 Penanganan Gagal Nafas Warna
23/55
LARYNGEAL MASK AIRWAY
Very useful in difficult intubation situation
7/27/2019 Penanganan Gagal Nafas Warna
24/55
Tracheal Intubation
- Gold standart in airway management.- Not easy to perform, complication can be serious
- Skill, experience and training are essential to minimaze complication
7/27/2019 Penanganan Gagal Nafas Warna
25/55
Clear and secure airwayReduced aspiration risk To fasicilitate intra tracheal suctionTo fasicilitate high concentration oxygensupport
Advantages of Tracheal Intubation
7/27/2019 Penanganan Gagal Nafas Warna
26/55
HipoxiaTrauma
Vomiting, aspirationHipertension, dysritmiaOne lung intubationOesophageal intubation
Bradycardia, vagal reflexCardiac arrest
Complication of tracheal intubation
7/27/2019 Penanganan Gagal Nafas Warna
27/55
TRACHEAL INTUBATION EQUIPMENT
7/27/2019 Penanganan Gagal Nafas Warna
28/55
7/27/2019 Penanganan Gagal Nafas Warna
29/55
7/27/2019 Penanganan Gagal Nafas Warna
30/55
Oral intubation technique
1
2
7/27/2019 Penanganan Gagal Nafas Warna
31/55
VISUALIZATION OF THE CORD
VOCAL CORD: MUST SEE THIS WHEN INTUBATE !!!
TRAKEA
7/27/2019 Penanganan Gagal Nafas Warna
32/55
BURP MANUEVER To aid visualization of the cordPush the cricoid cartilage back, up and right (BURP)
BURP
THYROID
CRICOID
ADAMS APPLE
7/27/2019 Penanganan Gagal Nafas Warna
33/55
3
4
7/27/2019 Penanganan Gagal Nafas Warna
34/55
5
7/27/2019 Penanganan Gagal Nafas Warna
35/55
Nasal Intubation technique
1 2
7/27/2019 Penanganan Gagal Nafas Warna
36/55
3
4
7/27/2019 Penanganan Gagal Nafas Warna
37/55
5
7/27/2019 Penanganan Gagal Nafas Warna
38/55
TRAI NI NG I S ESSENT I AL
7/27/2019 Penanganan Gagal Nafas Warna
39/55
Skilled trained personnel
Complete intubation equipmentPerformed less than 30 secondsPerform BURP Manuever Use high volume low pressure cuff ETT
Measures to prevent complication of trachealintubation
7/27/2019 Penanganan Gagal Nafas Warna
40/55
MANUAL POSITIVE PRESSURE VENTILATION WITHETT
7/27/2019 Penanganan Gagal Nafas Warna
41/55
2. Oxygen supplementationMost patient with ARF require supplemental oxygen. Oxygen transfer fromalveolar gas to capillary blood occurs by diffusion through alveolar-capillarymembrane, which driven by te oxygen partial pressure gradient between thePAO 2 (alveolus) and the PaO 2 (arterial blood) of the pulmonary capillaryblood. In most cases, the PAO 2 can be substantially increased by use of supplemental oxygen, thus increasing the gradient across the membrane andimproving PaO 2. This should be considered a temporizing intervention while
the primary etiology of hypoxemia is diagnosed and treated.The effectiveness of each oxygen supplement devices is determined by thecapacity of the device to deliver sufficient oxygen at high enough flow rate tomatch the patients spontaneous inspiratory flow rate.
Any entrained room air (FiO 2 = 0.21) will dilute (decrease) the FiO 2 of the
delivered gas in such a way that the tracheal FiO 2, and hence PAO 2 may beconsiderably lower than the FiO 2 delivered from the oxygen source.
7/27/2019 Penanganan Gagal Nafas Warna
42/55
Oxygen supplement systyem are classified as :1. Low oxygen, low flow devices e.g. nasal cannula2. Controlled oxygen, high flow devices e.g. venturi mask3. Variable oxygen, moderate flow devices e.g. aerosol face mask4. High oxygen, high flow devices e.g. reservoir face mask, Resuscitation Bag
Mask-Valve Unit.
1. Nasal CannulaShort prongs of the nasal cannula are inserted intothe nares. Oxygen (100%) is delivered throughcannula, but at low flow rates (0.5-5 L/min).The maximal tracheal FiO 2 is 0.40 - 0.50 (40-50%).Higher flow rates do not result in much higher FIO 2 levels and have drying and irritating effect on nasalmucosa. Comfortable and well tolerated by many
ARF patient in whom precise control of FiO 2 is notnecessary.
7/27/2019 Penanganan Gagal Nafas Warna
43/55
Flow (L/men) Desired FiO 2Measured FiO 2
Gibson et al Schachter et al
1 0.24 0.22 0.23
2 0.28 0.21 0.22 0.24
3 0.32 0.22 0.24 0.25
4 0.36 0.26
5 0.40 0.24 0.25
10 0.52 0.30 0.46
15 0.56 0.35 0.61
NASAL CANNULA
7/27/2019 Penanganan Gagal Nafas Warna
44/55
7/27/2019 Penanganan Gagal Nafas Warna
45/55
Gas flow (L/men) FiO2
4 8 0.24 / 0.28 / 0.35 / 0.40 /0.50 / 0.60
VENTURI MASK
3 A l F M k
7/27/2019 Penanganan Gagal Nafas Warna
46/55
3. Aerosol Face MaskThe mask with large side holes is attached by large-bore tubing to a nebulizer, which blends 100%oxygen and room air to deliver gas at a preset FiO 2 level. Flow matching can be evaluated by observingthe patient during spontaneous breathing. If theentire aerosol mist dissappears from mask duringinhalation, the patients inspiratory flow demands areprobably exceeding the capacity of nebulizer.
4. Reservoir Face MaskIncorporates a reservoir bag with the face mask fromwhich the patients breathes. The reservoir bag is
filled from the 100% oxygen supply source. The flowrate of oxygen is adjusted so that bag remainscompletely or partially distended throughout therespiratory cycle. FiO2: 0.6-0.9 (60-90%).
7/27/2019 Penanganan Gagal Nafas Warna
47/55
Flow (L/men) Desired FiO 2
5 -6 0.46 7 0.57 8 0.6
SIMPLE FACE MASK
Flow (L/men) Desired FiO 26 0.6
7 0.7
8 0.8
9 -10 0.9 0.99
RESERVOIR FACE MASK
7/27/2019 Penanganan Gagal Nafas Warna
48/55
7/27/2019 Penanganan Gagal Nafas Warna
49/55
7/27/2019 Penanganan Gagal Nafas Warna
50/55
3. NONINVASIVE POSITIVE PRESSUREVENTILATION
NPPV provides ventilatory assistance,controlled FiO 2 and positive airwaypressure without invasive artificialairway, thus avoids meany of thecomplication associated with intubationand mechanical ventilation.
Two form of NPPV: CPAP (ContinuousPositive Airway Pressure) and BIPAP(Bilevel Positive Airway Pressure).
CPAP: functionally equivalent to PEEP which delireved by a mechanicalventilator through face mask instead of ETT.
BIPAP: Combination of PSV (Pressure Support Ventilation) and CPAP
Best utilized in the alert, cooperative patient whose respiratory condition isexpected to improve in 48-72 hours, e.g. acute exacerbations of COPD.
7/27/2019 Penanganan Gagal Nafas Warna
51/55
4. TRACHEAL INTUBATION ANDMECHANICAL VENTILATION
TUJUAN KLINIS / INDIKASI PEMAKAIANTUJUAN KLINIS / INDIKASI PEMAKAIANVENTILASI MEKANIKVENTILASI MEKANIK
GAGAL NAFAS HIPOKSEMIK :
R ev er s e h y p o x em i a dgn pemberian PEEP dan konsentrasi O2tinggi (ARDS,edema paru atau pneumonia akut)
GAGAL NAFAS VENTILASI:
R ev er s e ac u t e r e s p i ra t o r y a c i d o s is
- Koma : trauma kepala, encefalitis, overdosis, CPR- Trauma med spinalis, polio, motor neuron disease
- Polineuropati, miastenia gravis
- Anesthesia (relaksan u/operasi, tetanus, epilepsi)
STABILISASI DINDING DADA:
F l ai l c h es t
MENCEGAH ATAU MENGOBATI ATELEKTASIS
7/27/2019 Penanganan Gagal Nafas Warna
52/55
Kriteria tradisional untuk bantuan ventilasi mekanikKriteria tradisional untuk bantuan ventilasi mekanik
35-45> 60Ventilasi (PaCO2-
mmHg)
25-65(FiO2 1.0)> 350P(A-aDO2) mmHg
75-100 (air) 35x/mMekanik (RR)
NORMAL RANGEINDIKASI VENTILASIPARAMETER
7/27/2019 Penanganan Gagal Nafas Warna
53/55
5. PHARMACOLOGIC ADJUNCTSMany disease causing ARF produce similar anatomic and physiologicderangements, incluiding bronchial inflammation, mucosal edema, smooth
muscle contraction, and increased mucos production and viscosity. Each of these processes may contribute to obstruction of airway gas flow, increasedairway resistance, V/Q mismatch, and elevated VD. Some pharmacologicagents have proven helpful in the care of such patients and may directly alter the shunt or dead space effect.
1. 2 AgonistsInhaled 2 agonists (e.g. Albuterol, Terbutaline, Metoproterenol sulfate )stimulate 2-adrenergic receptor causes bronchial and vascular smoothmuscle relaxation.
2. Anticholinergic agents
Ipratropium bromide competes with acetylcholine at bronchial receptor site,causing an increase in intracellular cGMP, signaling bronchial smooth musclerelaxation.
7/27/2019 Penanganan Gagal Nafas Warna
54/55
3. Corticosteroids
The central role of inflammation in obstructive airway disease is established, andthe benefit from aggressiv corticosteroid use in ashmatic patient with ARF is well
documented.4. Antibiotics
Bacterial infection (bronchitis/ pneumonia) frequently precipitates ARF. Antibioticsshoud be used when there is clinical suspicion that bacterial pulmonary infectionis present (e.g., change in sputum characteristics, pulmonary infiltrates on chst
radiograph, fever, leukocytosis)
7/27/2019 Penanganan Gagal Nafas Warna
55/55
Recommended